DUBLIN and CHICAGO, Sept. 26, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced U.S. FDA approval of a prospective, randomized pivotal clinical trial for the use of Infuse™ Bone Graft in Transforaminal Lumbar Interbody Fusion (TLIF) spine procedures. A TLIF is a type of surgery that fuses – or joins – bones of the spine …

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone